Greenyn Biotechnology Co., Ltd

Research Greenyn Biotechnology Co., Ltd (6846.TWO) on Bullrun: market cap TWD 1.55B, P/E 14.2, dividend yield 8.1%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is TWD 1.55B; P/E is 14.2; dividend yield is 8.1%.

Peer valuation comparison

Latest P/E is 14.24x versus a Healthcare sector median of 21.8x (34.6% below).

Latest dividend yield is 8.05% versus a Healthcare sector median of 2.4% (235.4% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18TWD 1.55B14.26.9%3.94

Dividend history

Latest trailing dividend snapshot: annual dividend/share 3.94 TWD, yield 8.1%.

About Greenyn Biotechnology Co., Ltd

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Greenyn Biotechnology Co., Ltd's market cap?

Greenyn Biotechnology Co., Ltd's market capitalization is TWD 1.55B.

What is Greenyn Biotechnology Co., Ltd's P/E ratio?

Greenyn Biotechnology Co., Ltd's price-to-earnings (P/E) ratio is 14.2.

Does Greenyn Biotechnology Co., Ltd pay a dividend?

Greenyn Biotechnology Co., Ltd has a dividend yield of 8.1%.

What does Greenyn Biotechnology Co., Ltd do?

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink.